Corixa completes $15 mil. initial venture capital financing round; Muc-1 antigen in Phase I for cancers.
CORIXA SECURES $15 MILL. IN INITIAL ROUND OF VENTURE CAPITAL FUNDING under the stewardship of President and CEO Steven Gillis, PhD. The private financing was provided by five West Coast venture firms: Enterprise Partners (Newport Beach, Calif.), Interwest Partners (Menlo Park, Calif.), Olympic Venture Partners (Kirkland, Wash.), Forward Ventures (San Diego) and Kleiner Perkins Caufield and Byers (Menlo Park). Gillis was the founder of Immunex and served as the Seattle-based biotech's exec VP-R&D. Corixa, also based in Seattle, was founded in September 1994. Gillis was acting CEO of Immunex following its merger with Lederle in 1993. He resumed his exec VP duties when Lederle exec Edward Fritzby was named Immunex chairman and CEO in January 1994.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth